🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Esperion Therapeutics, Inc.

ESPR Healthcare
$3.18 $0 (0.00%)
Market Cap: $819.46 M
Gurus Holding
3
Popularity Rank
#3180
% of Shares Held
0.42%
Net Activity (Q2 2026)
-$14.94 M

Guru Ownership Trend

Guru Analysis for Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics, Inc. (ESPR), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q2 2026, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $3.47 M.

Top institutional holders include George Soros and Mario Gabelli.

Institutional sentiment is currently Slightly Bearish. This is evidenced by a $14.94 M net outflow during the quarter.

Recent activity highlights George Soros who opened a new position. Conversely, Renaissance Technologies (RenTech) reduced exposure by 90.1%.

Key Holders

Top 5 by Value

Top 5 by Conviction

Recent Activity Breakdown (Q2 2026)

+$2.94 M
Total Buy Value
New Buys 2
Additions 0
-$17.87 M
Total Sell Value
Reductions 1
Sold Out 4

Guru Consensus (Q2 2026)

Based on recent activity
Net Sellers
5
Net Buyers
2

FAQs for Esperion Therapeutics, Inc. (ESPR)

Major holders include George Soros ($2.39 M), Mario Gabelli ($545,100), Renaissance Technologies (RenTech) ($506,232). According to the latest reported data, 3 tracked investment managers collectively hold approximately 1.09 M shares.

According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $14.94 M, with 2 managers increasing positions and 5 managers reducing holdings.

During the most recent reporting period, 1 managers trimmed their positions, while 4 fully exited ESPR. The total reported sell value was $17.87 M.

Yes, 2 managers opened new positions in ESPR, and 0 increased their existing holdings. The total reported buy value was $2.94 M.

Portfolio Manager % Portfolio Activity Shares Value Report Date
0.03% New Buy 757,358 $2.39 M Q2 2026
0.00% New Buy 172,500 $545,100 Q2 2026
0.00% Reduce -90.1% 160,200 $506,232 Q2 2026
Date
Insider Name
Transaction
Value
Shares
Position / Chg
SEC Form